Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT)

Autor:	M.A. Climent Duran, J. Rubio, S. Sandiego, R. Hajianfar, Joaquín Suárez, Begoña Mellado, Matías Castells, R. Villatoro, A. Montesa, M.I. Sáez, L. Heras Lopez, Maria J. Ribal, J.M. Piulats Rodriguez, M.J. Juan, D. Olmos Hidalgo, Òscar Reig
Rok vydání:	2017
Předmět:	Oncology medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Hematology Treatment results medicine.disease Androgen deprivation therapy Prostate cancer Docetaxel Internal medicine Medicine business medicine.drug
Zdroj:	Annals of Oncology. 28:v282
ISSN:	0923-7534
DOI:	10.1093/annonc/mdx370.031
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fc4d959c80e3105e4d5e18a0b6b6b5b7 https://doi.org/10.1093/annonc/mdx370.031 Zobrazit plný text záznamu